Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Eisai Stories

2014-04-14 12:27:47

Campaign Creates Awareness of Prescription Drug Option for Chronic Weight Management WOODCLIFF LAKE, N.J., April 14, 2014 /PRNewswire/ -- Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ(®) (lorcaserin HCl) CIV, an FDA-approved prescription therapy for chronic weight management. The advertisement will air on numerous channels including Lifetime, Oxygen and AMC. To view the multimedia assets associated with this release, please click:...

2014-04-08 08:30:17

Patent provides protection until 2033 and complements Epizyme's issued composition of matter claims for EZH2 inhibitors CAMBRIDGE, Mass., April 8, 2014 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted U.S. Patent No. 8,691,507 with claims that cover the identification of patients...

2014-03-31 04:20:57

WOODCLIFF LAKE, N.J., March 31, 2014 /PRNewswire/ -- Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license for DACOGEN(®) (decitabine) for Injection to Otsuka Pharmaceutical Co., Ltd., giving Otsuka full development and commercialization rights for the product in the former Eisai territories of the United States, Canada and Japan. Eisai will retain its rights for DACOGEN(®) in Mexico. In...

2014-03-13 08:29:07

Sisters Network® Inc. launches innovative pilot program designed to help address breast cancer disparities affecting the African American community HOUSTON and WOODCLIFF LAKE, N.J., March 13, 2014 /PRNewswire/ -- Sisters Network, the only national African American breast cancer survivorship organization, announced today the launch of Teens 4 Pink, a new program that aims to educate and empower African American teens to change the way their family members think and act about breast...

2014-03-12 08:27:11

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, March 12, 2014 /PRNewswire/ -- Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Johnson & Johnson (NYSE: JNJ), Express Scripts Inc. (NASDAQ: ESRX), Merck & Co. Inc. (NYSE: MRK), and Forest Laboratories Inc. (NYSE: FRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings...

2014-03-11 12:29:05

LONDON, March 11, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Alzheimer's Disease Therapeutics and Diagnostics: World Market 2013-2023 Report DetailsAlzheimer's medicine - your guide to technologies, trends and revenuesWhere's treatment of Alzheimer's disease heading? Visiongain's new report gives you revenue predictions for those drugs and diagnostic tests from 2013, helping you stay ahead.There you find financial data, R&D trends,...

2014-03-10 08:30:23

Company Appoints New Executive Leaders WOODCLIFF LAKE, N.J., March 10, 2014 /PRNewswire/ -- Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the appointments of Yuji Matsue as chairman and chief executive officer and Shaji Procida as president and chief operating officer, effective April 1, 2014. Mr. Matsue and Ms. Procida succeed current President and CEO Lonnel Coats, who will be retiring from Eisai in June 2014 after 18 years. Over the next few months,...

2014-02-27 16:28:46

- Conference Call and Webcast Scheduled for Today at 5:00 p.m. Eastern Time - SAN DIEGO, Feb. 27, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2013. "The 2013 US commercial launch of BELVIQ®, global expansion of our collaboration with Eisai, and the advancement of our research and development programs have positioned Arena for an outstanding year in...

2014-02-27 08:30:00

Patient Recruitment Now Underway at Treatment Centers Across the United States WOODCLIFF LAKE, N.J., Feb. 27, 2014 /PRNewswire/ -- Eisai Inc. today announced the start of a large, randomized Phase 3 trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel as a first- or second- line treatment for HER2-negative locally recurrent or metastatic breast cancer (MBC). Recruitment is currently active for this multicenter study, conducted in...

2014-02-21 08:25:37

Preclinical Study Results Published in the Journal Molecular Cancer Therapeutics Show Sustained Efficacy of EZH2 Inhibitor in Animal Models CAMBRIDGE, Mass., Feb. 21, 2014 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the publication of data from preclinical studies of the company's clinical candidate EPZ-6438 (E7438), a potent and selective...